Rx Medicare

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced the Company has initiated a second Phase 2a study of KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC). The study has begun enrollment of patients for the treatment of chronic neuropathic pain associated with chronic postherpetic neuralgia (PHN).

Read More…

Related Posts

• KAI Pharmaceuticals Initiates Third Phase 2a Study In Program To Develop KAI-1678 For The Treatment Of Neuropathic Pain
• Transdel Pharmaceuticals Announces Positive Phase 3 Study Results For Lead Topical Pain Drug Ketotransdel(R)
• China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase II Clinical Study Of Novel Menstrual Pain Drug
• QRxPharma Initiates Pivotal Phase 3 Study Of MoxDuo(TM)IR For Moderate To Severe Acute Pain
• Drug Used For Neuropathic Pain Relieves Discomfort From Abdominal Adhesions: Henry Ford Study
• Pacira’s Phase III Study Of EXPAREL(TM) Meets Primary Pain Relief Endpoint
• Positive Phase IIb Results For GSK1838262 (XP13512) Reported For Neuropathic Pain Associated With Post-Herpetic Neuralgia
• Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study For The Treatment Of Postherpetic Neuralgia (PHN)
• Javelin Pharmaceuticals Reports Ereska (Intranasal Ketamine) Phase III Trial Results In Postoperative Orthopedic Pain
• QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study For MoxDuo(TM) IV Pain Therapy
• AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
• Jazz Pharmaceuticals To Present Data From First Phase III Study Of Sodium Oxybate In Patients With Fibromyalgia
• Phase II Results For GSK1838262 (XP13512) Reported For Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
• AcelRx Announces Initiation Of Phase 2 Cancer Breakthrough Pain Program
• Study Findings Have Implications For Development Of Pain Relieving Drugs

Tags: 1678, development, expands, initiating, neuropathic, pain, pharmaceuticals, phase, program, study

This entry was posted on Friday, April 3rd, 2009 at 3:04 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.